

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

28 May 2015

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000


(11 pages by email)

Dear Madam

PRESENTATION TO INVESTORS

I attach a PowerPoint presentation as presented by Biotron Limited's Managing Director, Dr Michelle Miller, to investors.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn8116

BIOTRON LIMITED
(ASX:BIT)

**Mid-Clinical Stage Antiviral
Drug Development Company**

Broker Meet Biotech
May 2015

Dr Michelle Miller
Managing Director
+61 412 313329
mmiller@biotron.com.au
www.biotron.com.au

Biotron

A decorative horizontal strip at the bottom of the slide featuring a close-up of laboratory glassware, including test tubes and petri dishes, with blue and yellow liquid inside.






Forward Looking Statements

This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Biotron Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron’s current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

Biotron Snapshot


- Mid-clinical stage antiviral drug development company
 - New mode-of-action, first-in-class small molecule drugs
 - Phase 2 clinical programs for Hepatitis C virus (HCV) and HIV
 - BIT225 has demonstrated clinical activity
 - Seven clinical trials completed; one in progress
 - Headquartered in Sydney, Australia
 - Experienced management team with pharma and VC background
- **Key highlights over last 12 months**
 - **100% SVR12 (i.e. HCV cure) reported for HIV/HCV G3 Phase 2 trial**
 - **Impact on immune activation reported for HIV Phase 2a trial**
 - **Phase 2, three-month dosing HCV trial fully recruited**
 - **Key patents for BIT225 and other compounds issued in US and other key jurisdictions**

Biotron - Advanced Pipeline

INDICATION	COMPOUND	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
Hep C	BIT225					
HIV/Hep C	BIT225					
HIV	BIT225					
Next generation - HCV	BIT314					
Dengue	Leads					

Biotron

BIT225 – New Class of HCV Drug with Proven Clinical Track Record



- ✓ Over 180 people dosed with BIT225
- ✓ Positive data recorded in all trials
- ✓ Only one of its class (p7 inhibitor) in clinical trials
- ✓ Independently shown to have pan-genotype activity:
 - ✓ Active *in vitro* against all main HCV subtypes
 - ✓ Shown to be clinically active against hard-to-treat HCV G1 (1a and 1b) and G3
- ✓ Potential to fill the gaps left by other HCV drugs, e.g. HCV G3
- ✓ Relatively easy to make and formulate
- ✓ Very stable at room temperature – important for supply chains

Biotron


Large and Growing Global Market for Hepatitis C

- Forecast to grow to over \$19bn by 2016
 - 180 million infected worldwide (3% world population)
 - ~3 to 5 million in US & 30 million in China
- New drugs have demonstrated significant pricing power
 - Gilead's Sovaldi (Sofosbuvir) at US\$84,000 for a 12 week course
 - Best performing 'first year' sales: ~US\$10 billion
- Recent new HCV drug combinations not optimal
 - Lengthy treatment – 12 weeks or more
 - Not pan-genotypic – **BIT225 is pan-genotypic *in vitro***
 - Not as effective against HCV G3 – **BIT225 has good activity against HCV G3**
- Partnering still active
 - J&J partnered Achillion in US\$1.1 bn deal in May '15; Merck bought Idenix for US\$3.8 bn in June '14


HIV – Towards a Cure

- Infection rates at 20 year high
- Over 1.1 million people living with HIV in the USA;
1 in 6 unaware of diagnosis
- Patients need to stay on antiretroviral drugs (ART)
- Industry focused on developing drugs to eradicate or cure HIV infection


- Phase 2a trial showed BIT225 attacks HIV in macrophage cells *in vivo*, paralleling *in vitro* studies
- Potential benefits on immune aging and HIV-associated dementia
- **Potential for use in future eradication treatments**



(A) Untreated Controls



(B) BIT225 treated cells



Investment Proposition

- HCV and HIV are high growth, multi-billion dollar markets
 - Treatment gaps remain
- BIT225 is a novel approach with demonstrated promising efficacy in Phase 2a/2 clinical trials
 - Represents a new class of direct-acting HCV drugs
 - Potential to fill significant HCV treatment gaps
 - HCV Genotype 3
 - HIV/HCV co-infected patients
 - Cirrhotic patients
 - Potential to eradicate important HIV reservoirs, plus may impact on HIV-associated dementia
- Flexibility to combine with any other HCV and HIV drug combinations
- Significantly undervalued in comparison with other HCV companies

Outlook for 2015

- Complete BIT225-008 HCV trial currently in progress
 - Preliminary interim data expected mid-2015
- Investigational New Drug application(s) (INDs)
 - Engaged with FDA - pre-IND consultation HCV combination trial with DAA
 - File IND application(s) mid-2015
 - Currently completing studies required by FDA
- Expand earlier stage drug programs e.g. Dengue virus when funding available
- Continue commercialisation activities aimed at attracting partners
- Continue to promote company to local and international investment community

Financial Information

Key Financial Metrics

Ticker Code	ASX: BIT
Share Price (27 May 2015)	A \$0.125
Market cap	A \$32 million
12 Month Trading Range	A \$0.0864 – 0.1832
Shares Outstanding	279 million
Options (BITO)	50.7 million \$0.12 expiry 30/09/16
Cash Position (03/2015)	A \$2.2 million (excludes \$1.7 m received as R&D Tax incentive in April '15)

Board

Michael Hoy	Non-executive Chairman
Michelle Miller	Managing Director
Susan Pond	Non-executive Director
Rob Thomas	Non-executive Director
Denis Wade	Non-executive Director

12 Month Share Price Performance



Biotron